Wyeth mulls restructuring its global sales force

Share this article:
Wyeth said the restructuring of its U.S. sales force was only a start and that it is considering making similar changes globally.
"Obviously it is a first step. We're also looking internationally. Our European affiliates have started to look at how to optimize the sales force," Bernard Poussot, head of Wyeth's pharmaceutical operations, said in a Financial Times report.
Last month Wyeth said it would use inside, part-time sales representatives in the U.S. to complement its full-time sales force, which is being reduced by about 25% to 30%.
Adding the part-timers will result in a net sales-force reduction of about 15%, Poussot said. Wyeth has deployed part-timers in its consumer division for the past few years.
As reported in MM&M (July 2005), the drug maker began piloting part-timers in its pharmaceuticals division in July and said it will fully implement them by year's end.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.